The corporate team at Penningtons Manches Cooper has advised Oxford Endovascular, an Oxford-based medtech company spun-out from Oxford University, on its Series A funding round.
The funding round, which closed at US$10 million, was led by new investors Vulpes Investment Management and included existing investors Oxford Sciences Innovation PLC, Parkwalk Advisors and the University of Oxford with other private and institutional investors also following on.
Oxford Endovascular is working to develop a device to treat brain aneurysms. The funding will further enable them to complete development work and gain first in-human data through an early feasibility clinical study.
Penningtons Manches Cooper has advised Oxford Endovascular on a range of legal matters including its September 2020 special pandemic investment from EIT Health. Corporate senior associate Attilio Leccisotti, who has advised Oxford Endovascular since its establishment, led the team on this transaction, working with corporate partner James Went.